Answers are grounded in this paper and cite their sources.
Inhibition of Chk1 kinase has garnered attention as a possible complement to DNA-damaging chemotherapeutic agents, widening their therapeutic window. As a result, several distinct classes of Chk1 inhibitors have been recently identified with selected compound advancing to clinical trials stage. This review focuses on the challenges and recent progress achieved in this area from a medicinal chemistry perspective.
No takes yet. Share an insight, caveat, or question.
Arrington et al. (2007) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: